Key Points {#FPar1}
==========

A population pharmacokinetic model was established to estimate the pharmacokinetics characteristics in Chinese geriatric patients with pulmonary infections.The model could be used to develop an initial assessment of vancomycin dosing in geriatric patients.

Introduction {#Sec1}
============

Pulmonary infections are common in hospitalized patients. Vancomycin is the first choice for the treatment of pulmonary infections caused by Gram-positive staphylococcus and is considered the last defense against Gram-positive bacterial infections \[[@CR1]\]. These infections are usually more severe in geriatric patients than in younger adult patients. Bacteria frequently develop resistance to antibiotics \[[@CR2]\]. Drug-resistant bacteria as well as adverse drug reactions are more likely occurrences in the elderly, which means that drug therapy in this population fails or results in death at a higher rate \[[@CR3]\].

Vancomycin, a bacteriostatic glycopeptide antibiotic, remains the most frequently used antibiotic in critically ill patients for the treatment of bacterial infections due to methicillin-resistant *Staphylococcus aureus*. One of the common adverse reactions of vancomycin is acute kidney injury (AKI) \[[@CR4], [@CR5]\], which has a high incidence and a short incubation period (it may occur in 48 h). Presently, the conventional guidance is that therapeutic drug monitoring (TDM) should be carried out within 48 h after stability, but the warning signs of injury may be delayed past this timeframe. However, if the pharmacokinetics of a patient can be predicted by using a population pharmacokinetic (PopPK) model based on renal function, the dose may be adjusted prior to dispensing the medication so that it is safer and more effective, which may effectively reduce the incidence of vancomycin AKI. Vancomycin-induced acute kidney injury (VI-AKI) occurs more readily in geriatric patients with pulmonary infections, so there is a more urgent need in these patients for an accurate dosage regimen.

The renal function of the elderly gradually decreases with age, which has a significant impact on the pharmacokinetics of vancomycin. A larger volume of distribution and a longer half-life of vancomycin have been observed in elderly patients as compared to younger adult patients \[[@CR6]\]. Geriatric patients with pulmonary infections usually have poor nutrition, are associated with hypoalbuminemia, and suffer from internal environmental disorders such as hypokalemia, hyponatremia and metabolic acidosis \[[@CR4], [@CR6]\]. Thus, the elderly and the young are distinguished in terms of their pharmacokinetic characteristics. However, the pharmacokinetics of vancomycin in the elderly population are less known \[[@CR6]\].

Currently, there are limited PopPK models for vancomycin studies in geriatric patients. It is necessary to establish a PopPK model and individual treatment plans for elderly patients to improve the safety and effectiveness of vancomycin therapy in geriatric patients.

The objective of the present study was to estimate the PopPK of vancomycin in Chinese geriatric patients (age ≥ 65 years) with pulmonary infections.

Ethics Approval {#Sec2}
===============

This study was approved by the Clinical Research Ethics Committee of Peking University First Hospital on December 15, 2015. The approval number is 2015\[998\].

Methods {#Sec3}
=======

Patients and Data Collection {#Sec4}
----------------------------

All patients of Peking University First Hospital between January 2012 and December 2016 who satisfied the screening criteria were included in the study. The clinical data of these patients were retrospectively collected.

The inclusion criteria were as follows: (1) age ≥ 65 years, (2) patient had received intravenous vancomycin infusion for more than 2 days during hospitalization due to pulmonary infection \[hospital-acquired pneumonia (HAP) or community-acquired pneumonia (CAP)\], and (3) patients had received TDM more than once.

The exclusion criteria were as follows: (1) patient had multiple organ failure, renal replacement therapy or low volume shock, or (2) patient's clinical data were lacking.

For those patients who qualified for the study, we collected basic information, vancomycin treatment information, TDM information, laboratory test results and information about concomitant drugs. The basic information consisted of sex, age, height and weight; the vancomycin treatment information consisted of dosage, interval, infusion time, and the number of infusions; the TDM information consisted of monitoring time and results; the laboratory test results consisted of serum creatinine, alanine aminotransferase, aspartate aminotransferase, total protein, albumin, total bilirubin, and urea nitrogen; and concomitant drugs consisted of amphotericin B, amikacin, diuretics (furosemide, torsemide, hydrochlorothiazide, spironolactone), and vasoactive drugs (catecholamines, epinephrine, norepinephrine).

Blood Sampling and Vancomycin Assays {#Sec5}
------------------------------------

The vancomycin dosing regimen consisted of 500 mg (every 6 h, 8 h, 12 h, 24 h, 48 h) and 1000 mg (every 8 h, 12 h), for 1.5--2 h intravenous infusion. The TDM usually occurred 0.5--2 h before and after the fourth or fifth dose of vancomycin, which were regarded as steady-state concentrations. All the TDM data were collected. All serum concentrations of vancomycin were determined via the chemiluminescence microparticle immunoassay method with the ARCHITECT i1000 system (Abbott Laboratories, Chicago, IL, USA). The coefficient of variation was less than 10%, and the linear range was between 3 and 100 mg/L.

PopPK Analysis {#Sec6}
--------------

The vancomycin PopPK model was established and simulated with nonlinear mixed effect model software NONMEM^®^ (v.7.3.0; ICON Development Solution, Ellicott City, MD, USA), and the Rstudio environment (v.98.1103, <https://www.rstudio.com/>) was used for statistical analysis and plotting. A first-order conditional estimation method with an inter- and intra-subject variability interaction (FOCE-I) option was used to calculate pharmacokinetic parameters.

The serum concentrations in the study were trough concentrations in steady-state; therefore, we established a one-compartment model that with first-order elimination (ADVAN1 TRANS2) was used as a base model to describe the relationship between serum concentration and time. The inter-individual variability of the model was formulated with an exponential random-effects formula, and the formulae were as follows:$$\documentclass[12pt]{minimal}
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CL~i~ is the relative clearance of patient i, *θ*~CL~ the population typical value, and *η* the individual variation. The results show normal distribution with a mean of 0 and a variance of *ω*2 (*N* (0, *ω*^2^)).

The residual unexplained variability was fitted with a mixture model. The formula used was as follows:$$\documentclass[12pt]{minimal}
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The covariates examined in this study were sex (SEX), AGE, weight (WT), serum creatinine (SCR), creatinine clearance (CL~CR~), alanine aminotransferase (ALT) and aspartate aminotransferase (AST), urea nitrogen (BUN), total protein (TP), albumin (ALB) total bilirubin (TBIL), amikacin, amphotericin B, diuretics, and vasoactive drugs. CL~CR~ was calculated using the Cockcroft--Gault formula. First, we selected covariates that could significantly improve the fitness of the model. Then, we added covariates into the base model and subsequently observed a change in the minimum value of the objective function (OFV); the covariate significantly enhanced the fitness of the model (*χ*^2^, *p* \< 0.05) once the OFV decreased by more than 3.84, determining which enhancement could be added into the whole model. The selected covariates were added into the base model in the order of the degree of OFV decrease, starting with the covariate that caused the highest degree.

A backward elimination method was applied to determine the final model, and the covariates were eliminated in the reverse order they were used to build the total quantity model. We observed a change in the minimum value of the OFV. If the OFV increased by more than 6.64, the covariate significantly improved the fitness of the model (*χ*^2^, *p* \< 0.01), and persisted in the model. The influences of continuous covariates and categorical covariates were validated by formulae as follows:
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Model Evaluation {#Sec7}
----------------

The internal verification of the final model was carried out by goodness-of-fit plots and statistical methods. Scatter plots were drawn of population-predicted (PRED) and individual-predicted (IPRED) concentrations versus observed concentrations (DV), and TIME versus the conditional weighted residuals (CWRES) and weighted residuals (WRES). A *Y* = *X* scatter trend line was added to the IPRED-DV and the PRED-DV. The closer the slope was to 1, the better the fit of the final model. The NPDE method was performed with Rstudio (v.0.98.1103, <https://www.rstudio.com/>). NPDEs were calculated to evaluate the predictive properties of the model. A simulation database was built, and the NPDE parameters were calculated. The mean, variance, skewness and kurtosis of the results were tested with statistical methods to assess whether the distribution approximated the standard normal distribution. We performed statistical tests associated with NPDE that consisted of: (1) a *t* test to determine whether there was a significant difference between the mean value of NPDE and 0; (2) a Fisher test to determine whether there was a significant difference between NPDE variance and 1; and (3) a Shapiro--Wilks test to determine whether there was a significant difference between the distribution of NPDE and the normal distribution. Histograms of NPDEs, plots of NPDE versus TIME and NPDE versus predicted concentrations were generated and used as additional simulation-based diagnostics. A total of 1000 bootstrap datasets was generated to test the statistical verification, reliability and stability of the PopPK model. The observed dataset was resampled with replacement data to generate a new dataset with the same size and population characteristics as the original dataset. The robust rate, point estimates and 95% confidence interval of the model were evaluated. If the results satisfied the conditions of success ratio of 1000 bootstraps \> 90% and each parameter \< 95% confidence interval, the model was considered more stable.

Simulation {#Sec8}
----------

We used the simulation module of the NONMEM software to simulate the concentration of vancomycin 1000 times.

Results {#Sec9}
=======

The development of the model was based on a database of 125 observations from 70. There were 49 males and 21 females in the study. The mean age of patients was 78.3 (± 6.96) years. A total of 57 patients (81.4%) had HAP while 13 patients (18.6%) had CAP. The number of concentration data points derived from each patient ranged from 1 to 5 (mean = 1.79). The basic information about the patients is shown in Table [1](#Tab1){ref-type="table"}. Normally distributed continuous variables were expressed as the mean ± standard deviation, and non-normally distributed continuous variables were presented as the median (interquartile range).Table 1Demographic and pathophysiological characteristics of study patientsCharacteristicStatistics resultsMale/female *n*49/21AGE/(years) (mean ± SD)78.3 ± 6.96Height/cm (mean ± SD)161 ± 10WT/kg (mean ± SD)60.7 ± 10.2Daily dose/g/day (mean ± SD)1.55 ± 0.770Serum concentration/mg/L (mean ± SD)17 ± 8.03SCR/μmol/L (mean ± SD)90.6 ± 31CL~CR~/mL/min (mean ± SD)56.3 ± 22.1BUN/mmol/L (minimum--maximum)10.5 (3.18--86)TP/g/dL (mean ± SD)59.8 ± 8.92ALB/g/dL (mean ± SD)29.3 ± 4.12HAP *n* (%)57 (81.4%)CAP *n* (%)13 (18.6%)Respiratory failure *n* (%)46 (65.7%)Hypertension *n* (%)38 (54.3%)*WT* weight, *SCR* serum creatinine, *CL*~*CR*~ creatinine clearance rate, *BUN* blood urea nitrogen, *TP* total protein, *ALB* albumin, *HAP* hospital-acquired pneumonia, *CAP* community-acquired pneumonia

The results showed that CL~CR~, WT and AGE significantly improved the initial model. Consequently, CL~CR~, WT, and AGE were added to build out the whole model. However, when we added AGE to the model, the OFV was \< 6.64, so AGE was not used in the final model.The final model is shown in Eqs. ([9](#Equ9){ref-type=""}) and ([10](#Equ10){ref-type=""}). The modeling process is shown in Table [2](#Tab2){ref-type="table"}. When the influences of continuous covariates were validated by Eq. ([3](#Equ3){ref-type=""}), the OFV was satisfied better.$$\documentclass[12pt]{minimal}
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                \begin{document}$$V_{d} ({\text{L}}) = 154.$$\end{document}$$Table 2Model construction processModel IDOFVΔOFV*P* valueModeling1617.755----Basic modelCovariates on CL 2606.197− 11.558*P* \< 0.05Add CL~CR~ on CL in model 1 3608.973− 8.782*P* \< 0.05Add AGE on CL in model 1 4609.196− 8.559*P* \< 0.05Add WT on CL in model 1Forward inclusion 5601.501− 4.696*P* \< 0.05Add AGE on CL in model 2 6602.416− 3.781*P* \> 0.05Add WT on CL in model 2Backward elimination 7608.9737.472 \> 6.64*P* \< 0.01Sub CL~CR~ on CL in model 6 8606.1974.696 \< 6.64*P* \> 0.01Sub AGE on CL in model 6Model 2 as final model*WT* weight, *CL*~*CR*~ creatinine clearance rate, *OFV* objective function value

We drew a scatter plot of continuous covariates and CL fitted by a basic model, and a linear trend line was added to the scatter plot. The results are shown in Fig. [1](#Fig1){ref-type="fig"}. SCR and AGE were noted to be inversely related to CL. CL~CR~ and WT were noted to be positively related to CL.Fig. 1The correlation analysis between the clearance rate (CL) value of the vancomycin base model and continuous covariates. **a** Weight (*WT*) versus CL, **b** AGE versus CL, **c** serum creatinine (*SCR*) versus CL, **d** creatinine clearance rate (*CL*~CR~) versus CL

We drew scatter plots of PRED and the IPRED versus the DV. We also drew scatter plots of TIME versus WRES or CWRES. The results show that the value of WRES ranges from − 3  to 3, and the value of CWRES ranges from − 3 to 3 (see Fig. [2](#Fig2){ref-type="fig"}; Table [3](#Tab3){ref-type="table"}).Fig. 2Diagnostic goodness of fit plots of the final model. **a** Observed concentration (*DV*) versus population-predicted concentration (*PRED*), **b** DV versus individual predicted concentration (*IPRED*), **c** conditional weighted residuals (*CWRES*) versus time, **d** weighted residuals (*WRES*) versus timeTable 3Comparison of the base and final modelsParameterFinal modelBase modelValueRSE%ValueRSE%*θ*~1CL~ (L/h)2.456.9%2.477.94%*θ*~2*V*d~ (L)1549.2%14217.0%*θ*~3CLCR~ (mL/min) on CL0.54235.1%----*ω* ~CL~0.17421.2%0.23540.6%*ω* ~*V*~0.33937.8%0.21346.8%*σ* ~1~0.065734.2%0.072248.8%*σ* ~2~0 FIX--0 FIX--*θ*~*1CL*~ population parameter of CL, *θ*~*2Vd*~ population parameter of *V*~d~, *θ*~*3CLCR*~ population parameter of CL~CR~, *ω*~*CL*~ intra-individual variation of CL, *σ*~*1*~ proportional residual variation, *σ*~*2*~ additive residual variation, *CL*~*CR*~ creatinine clearance rate

An internal validation of the NPDE results showed that the mean and variance of the final model are 0.248 and 1.28, respectively; the values of the *t* test, Fisher test and Shapiro--Wilks test are 0.0158 (*p* \> 0.001), 0.0388 (*p* \> 0.01) and 0.861 (*p* \> 0.05), respectively. The numerical results show that the distribution of the final model was close to normal distribution, and the model fit well (see Fig. [3](#Fig3){ref-type="fig"}). The *y* = *x* chart, histogram and random scatter plot showed a similar trend with a normal distribution. The results indicate a good fit, and the 1000 bootstrap statistical verification showed that the model robust rate is 92.1%, the parameter values are all within the 95% confidence interval, and the 95% confidence interval estimate did not consist of 0, indicating that the model was stable. The results are shown in Table [4](#Tab4){ref-type="table"}.Fig. 3Normalized predictive distribution error (NPDE) of the population pharmacokinetics final model for vancomycin. **a** Quantile--quantile plot of NPDE versus normalized distribution, **b** the distribution chart of predictive distribution error, **c** NPDE versus time, **d** NPDE versus PREDTable 4Bootstrap results for the final model; 1000 iterations; success rate 92.1%ParameterNONMEM parameterBootstrap 95% CIBootstrap medianBootstrap 95% CI*θ*~1CL~(L/h)2.45(2.02, 2.88)2.43(2.09, 2.81)*θ*~2*V*d~ (L)154(110, 197)154(117, 191)*θ*~3CLCR~ (mL/min) on CL0.542(0.141, 0.942)0.538(0.206, 0.878)*ω* ~CL~0.174(0.076, 0.272)0.162(0.092, 0.256)*ω* ~*V*~0.339(0.079, 0.598)0.289(0.121, 0.557)*σ* ~1~0.0657(0.0177, 0.114)0.0691(0.0254, 0.106)*σ* ~2~0 FIX--0 FIX--*CL*~*CR*~ creatinine clearance rate, *CL* clearance, *V*~*d*~ volume of distribution

The simulation results show that the initial drug regimen should be established according to the CL~CR~ of patients. The results are shown in Table [5](#Tab5){ref-type="table"}. For patients whose CL~CR~ is \> 50 mL/min, the initial vancomycin dosing regimen can be the full dose of 1000 mg administered every 8 h (18.41 ± 8.95 mg/L) or q 12 h (15.10 ± 7.02 mg/L). The concentration, however, may exceed 20 mg/L if the CL~CR~ of the patient is not stable at a dosing regimen of 1000 mg, every 8 h. For patients whose CL~CR~ is ≤ 50 mL/min, the initial dosing regimen can be modified to 1000 mg, q 12 h (17.63 ± 8.44 mg/L) since q 8 h may lead to a high concentration.Table 5Simulation data (simulation times = 1000)Dosage regimenConcentration (mg/L)Total (average plasma concentration)CL~CR~ \> 50 mL/minCL~CR~ \< 50 mL/min1000 mg, q 8 h19.26 ± 9.5018.41 ± 8.9520.72 ± 9.531000 mg, q 12 h16.02 ± 7.5115.10 ± 7.0217.63 ± 8.441000 mg, q 24 h10.29 ± 4.699.40 ± 4.3811.96 ± 5.30500 mg, q 6 h11.22 ± 5.8510.83 ± 4.5711.88 ± 4.36500 mg, q 8 h9.82 ± 4.979.38 ± 3.6510.57 ± 3.57500 mg, q 12 h7.98 ± 3.947.52 ± 2.688.79 ± 3.43500 mg, q 24 h5.06 ± 2.534.62 ± 1.355.89 ± 2.90*CL*~*CR*~ creatinine clearance rate, *q* × *h* every × hours

Discussion {#Sec10}
==========

Our study aims to estimate the PopPK model of vancomycin in Chinese geriatric patients (age ≥ 65 years) with pulmonary infections because there is no suitable PopPK model for this population. After retrospectively collecting 125 observations from 70 patients of Peking University First Hospital, we built the following PopPK model: CL(L/h) = 2.45 × (CL~CR~/56.28)^0.542^, (9) *V*~d~(L) = 154 (10).

We performed an internal validation and simulation to assess the final model. The distribution of the final model was close to normal distribution, and the model had good fit.

Our study found that CL~CR~ is the only covariate that affects the clearance parameter in geriatric patients with pulmonary infections. Overall, 90% of vancomycin is excreted though the kidney. Renal function is undoubtedly one of the important factors that affects the pharmacokinetics of vancomycin, and the CL~CR~ is a substantial factor related to age, weight and creatinine. Additionally, many studies of PopPK models of vancomycin in adults have demonstrated that CL~CR~ is one of the most important covariates that affect vancomycin pharmacokinetics. In these studies, the typical value of CL in the final model was 2.45 L/h. We placed the average values of CL from these studies into our final model and obtained the typical values of 3.58 L/h and 2.95 L/h \[[@CR8], [@CR9]\]. In the study that found a typical value of 3.58 L/h, the subjects were adult patients. However, research has shown that the CL values of geriatric patients are smaller than those of adult patients \[[@CR3]\]. In the study that found a typical value of 2.95 L/h, the subjects were geriatric patients and the typical values were similar. The models from all the studies we reference are shown in Table [6](#Tab6){ref-type="table"}.Table 6Population pharmacokinetic model of vancomycin in adult patientsAuthorPopulationSample sizeAge (years)No. of modelPopPK modelLin \[[@CR10]\]Adult Chinese patients17951.6 ± 16.91CL (L/h) = 7.56 × (CL~CR~/104.71)^0.886^; *V*~d~ (L) = 101Deng \[[@CR7]\]Adult Chinese patients72NA1CL (L/h) = 4.90 (CL~CR~ ≥ 80 ml/min);\
CL (L/h) = 0.0654 × CL~CR~ if CL~CR~ \< 80 ml/min.; *V*~d~ (L) = 47.76Leu \[[@CR11]\]MRSA infectors76NA1CL (mL/min) = CL~CR~;\
*V*~d~ (L) = (0.17 × AGE) + (0.22 × ABW) + 15Revilla \[[@CR12]\]ICU patients19161.1 ± 16.31CL (mL/min/kg) = 0.67 × CL~CR~ + AGE-0.24;\
*V*~d~ (L/kg) = 0.82 × 2.49 × A\
A = 0 or 1 if SCR ≤ or SCR \> 1 mg/dlSanchez \[[@CR6]\]Adult patients14155 ± 14.582CL (L/h) = 0.157 + 0.563 × CL~CR~;\
*V*~1~ (L) = 0.283 × TBW; *V*~2~ (L) = 32.2 × AGE/53.5; *Q* = 0.563 × TBWTanaka \[[@CR13]\]Adult patients16474 (17--95)1CL (L/h) = 0.875 × GFR; *V*~d~ (L) = 0.864 (L/kg)Dolton \[[@CR14]\]Burn patients7034 (15--88)2CL (L/h) = 4.7 × (CL~CR~/6.53);Control patients72 (38 \~ 95)*V*~1~ (L) = 68.4 × WT/70-33.1 × BURN;\
*V*~2~ (L) = 73(L/h) × WT/70; *Q* (L/h) = 4.54Yamamoto \[[@CR15]\]Healthy people10621.7 (20 \~ 25)2CL (L/h) = 3.83, if CL~CR~ ≤ 85 mL/min\
CL (L/h) = 0.0322 × CL~CR~ + 0.32, if CL~CR~ \< 85 mL/min; *V*~d~ (L) = 0.206 × WTLlopis-Salvia \[[@CR16]\]Adult patients5060 (18--81)2CL(L/h) = 0.034 × CL~CR~ + 0.015 × TBW;\
*V*~1~ (L/h) = 0.414 × TBW; *V*~2~ (L/kg) = 1.32 × TBW; *Q* (L/h) = 7.48Staatz \[[@CR17]\]Adult patients10266 (17--7)1CL(L/h) = 2.97 × (1 + 0.0205 × (CL~CR~ − CL~CRmedian~));\
*V*~d~ (L/h) = 1.24Buelga \[[@CR18]\]Blood cancer patients21564.7 ± 11.31CL (L/h) = 1.08 × CL~CR~; *V*~d~ (L) = 0.98 × WT(L/kg)Yasuhara \[[@CR19]\]Adult patients19064.3 (19.3--89.6)2CL (L/h) = 0.0478 × CL~CR~ (CLce ≤ 85 mL/min)\
CL (L/h) = 3.51 × CL~CR~ (CL~CR~ \> 85 mL/min);\
*V*~1~ = 60.7; *V*~2~ = 24.63; *Q* = 60.7Lin Zhong \[[@CR20]\]Adult infected patients9852.9 ± 17.21CL (L/h) = 0.18 × (Scr)^0.19^ × (Sex)^0.31^;\
*V*~1~ (L) = = 20.85 × (Scr)^0.52^ × (Age)^0.23^ × (WT)^0.98^Liu Chang \[[@CR21]\]Adult patients27640.83 ± 21.231CL (L/h) = (3.35 × Infection + (1-Infection) × 6.74) × e^0.0829^;\
*V*~d~ (L) = (42.8 × Infection + (1-infection) × 26.6) × e^0.147^\
Infected population Infection = 1, no-infected population Infection = 0Wang Rong \[[@CR22]\]Severe patients in neurosurgery4253 ± 142CL (L/h) = 3.55 × (CL~CR~/94.1)^0.84^;\
*V*~1~ (L) = (62.8 − ALB) × (AGE/57.9)^0.37^;\
*V*~2~ (L) = 35.4 × (1 + (0.81 × GEND) × e^(AGE−57.9)^ × 0.03; *Q* = 7.04Zhang Jin \[[@CR8]\]Elderly patients6473.99 ± 6.901CL (L/h) = 4.23 × (CL~CR~/76.82)^0.774^; *V* (L) = 71.4Chen Bing \[[@CR23]\]Adult patients16947.3 ± 19.62CL (L/h) = 4.02 × (CL~CR~/90)^0.58^; *V*~1~ (L) = 21.8; *V*~2~ (L) = 67.1; *Q* (L/h) = 6.01He Xiaorong \[[@CR24]\]Elderly patients26076.79 ± 11.181CL (L/h) = (1.71 + 8.31 × (1 − e^(−0.0113(L/h)×CL^~CR~^)^)) × 0.475^(AGE/72)^\
*V*~d~ (L) = 26.2 × 0.475^\[AGE/72\]^Weng Fangjuan \[[@CR25]\]Adult Gram-positive bacterial infection in ICU103NA1CL (L/h) = 0.044 × CL~CR~; *V*~1~ (L) = 0.542 × AGE; *V*~2~ (L) = 44.2;\
*Q* (L/h) = 6.95Wu Wei \[[@CR26]\]Adult patients10051.75 ± 16.541CL (L/h) = 7.56 × (CL~CR~/104.7133)^0.886^; *V*~d~ (L) = 101Meng Long \[[@CR27]\]NA129NA2CL (L/h) = 3.56 × (CL~CR~/94.1)^0.85^;\
*V*~1~ (L) = (31 − (ALB-33.1) × 108) × (AGE/57.9)^0.34^;\
*V*~2~ (L) = 21.6 × (1 + 1.27 × SEX); *Q* (L/h) = 5.94Wang Yang \[[@CR28]\]Severe lower respiratory tract infection patients70NA2CL (L/h) = 1.67 × e^(*η*1)^,\
*V*~1~ (L) = 33.04 × \[1 − 0.199 × (60/SCR)\] × *e*^(*η*2)^\
*V*~2~ (L) = 19.29 × e^(*η*4)^\
*Q* (L/h) = 7.08 × 2.053^(ALB)^ × e^(*η*3)^,*CL*~*CR*~ creatinine clearance rate, *V*~d~ volume of distribution, *V*~1~ volume of distribution of the central compartment; *V*~2~ volume of distribution of the peripheral compartment, *Q* intercompartmental clearance, *GEND* gender, *WT* bodyweight, *SCR* serum creatinine

The simulation results show that the initial dosing regimen should be made according to the CL~CR~ of patients. For patients whose CL~CR~ is \> 50 mL/min, the initial regimen can be 1000 mg, q 8 h (18.41 ± 8.95 mg/L) or q 12 h (15.10 ± 7.02 mg/L). However, the concentration may exceed 20 mg/L with dosing of 1000 mg, q 8 h if the CL~CR~ of the patient is not stable. For patients whose CL~CR~ is ≤ 50 mL/min, the initial dosing regimen can be 1000 mg, q 12 h (17.63 ± 8.44 mg/L) since q 8 h may lead to a high concentration.

There are some limitations to our study. The concentration values reflect only steady-state trough concentrations since the concentration data were obtained from routine TDM. Furthermore, our study was a retrospective study, which may affect the accuracy of some of the data and influence the final model. Further research, including a prospective study, should be carried out to build a more precise model.

Conclusion {#Sec11}
==========

A one-compartment PopPK model of vancomycin in Chinese geriatric patients with pulmonary infections was established. CL~CR~ was found to be the only covariate that affected vancomycin pharmacokinetic parameters. The predictive performance of the PopPK model in geriatric patients differed significantly from that of the PopPK model in adult patients.
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